COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo

Process Development and Scale Up

ADC Development - We offer process development and scale-up through Tox manufacturing and into GMP manufacturing. Our ‘New Process Introduction’ team works closely with the Development team, ensuring the final process transferred into the GMP manufacturing suite is robust. We enjoy a 100% success rate of introducing new projects to GMP developed through our process development group, which supports the client's program through clinical trials and into the commercial stage.

Process Development Activities

  • Preclinical proof of concept studies
  • Formulation development studies
  • Conjugation chemistry optimisation
  • Development and optimization of supporting purification techniques
  • Robustness and process characterization studies

Unparalleled experience

  • Conjugation chemistry experience with non-cleavable, cleavable and enzyme labile linkers
  • Experience with all major drug platforms
    • Auristatins
    • Maytansanoids
    • Duocarmycions
    • Pyrrolobenzodiazepines
    • Other proprietary drugs such as non-cytotoxic small molecule payloads and chelating conjugates for Radio immunotherapy/Imaging
  • Traditional and site-specific conjugation experience
  • Experience in conjugation to IgG1, IgG2, IgG4, engineered antibodies and fragments
  • Capability to work from mg to hundred-gram scales